Secondary Primary Lung Cancer After Esophageal Cancer: A Population-Based Study of 44,172 Patients

Yadong Gao  ( gaoyadong666@163.com )
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Jianwei Qiu
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Liugen Gu
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Yanmei Yang
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Haifeng Kang
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Yong Zhang
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Yan Zhang
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Shenglai Zhang
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Junbo Qian
Nantong City No 1 People's Hospital and Second Affiliated Hospital of Nantong University

Research

Keywords: esophageal cancer, lung cancer, secondary primary malignancy, overall survival, population-based study, multiple imputation

DOI: https://doi.org/10.21203/rs.3.rs-37461/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: The present study aimed to assess the incidence, characteristics, and survival of secondary primary lung cancer after primary esophageal cancer (EC-LC).

Methods: The patients with esophageal cancer (EC) who developed SPLC and patients with first primary lung cancer (LC-1) were retrospectively reviewed in the Surveillance, Epidemiology, and End Results 18 registries covering 2000 to 2016. The risk of secondary primary lung cancer using standardized incidence ratio (SIR) was calculated among patients with EC. Overall survival and characteristics were compared between patients with EC-LC and patients with LC-1.

Results: In comparison with the general population, the patients with EC had a higher risk for developing secondary primary lung cancer (SIR =1.86, 95% confidence interval (CI): 1.69-2.05). There was a significant difference with regard to the year of diagnosis, sex, grade and stage between the secondary primary lung squamous carcinoma after EC (EC-LUSC) and first primary lung squamous carcinoma (LUSC-1) patients. A statistically significant difference with respect to race, sex, age, year, grade and stage was found between the secondary primary lung adenocarcinoma after EC (EC-LUAD) and first primary lung adenocarcinoma (LUAD-1) patients. A history of EC was found to be an independent risk factor of death for lung squamous carcinoma and lung adenocarcinoma patients in localized stage based on multivariate Cox regression analysis, propensity score-matching analysis and multiple imputation.

Conclusion: There is a significantly increased risk of secondary primary lung cancer in EC survivors and a history of EC adversely affects overall survival in individuals who subsequently develop localized EC-LUSC and EC-LUAD. Clinicians should moderately strengthen lung tissue protection during the management of EC patients.

Background

Esophageal cancer (EC) is the sixth most common cause of cancer-related death, leading to approximately four hundred thousand deaths per year[1]. Although esophageal cancer incidence rates in U.S. have tended to decrease[2-3], the incidence rates of secondary primary malignancy (SPM) after EC have tended to increase because of increasing numbers of long-term cancer survivors[4]. Previous several population-based studies have demonstrated that patients with EC are at increased risk of developing SPM, with standardized incidence ratios (SIRs) range from 1.15 to 3.53 in comparison with the general population[5-7]. Lung cancer (LC) is one of the most frequently occurring SPM after an EC. There have been several studies describing an increased incidence of secondary primary lung cancer (SPLC) in the EC population, which may be explained by the concept of “field cancerization”[5-10]. Notwithstanding several reports have discussed the risk of SPMs, including SPLC, most of these exclusively focused on the frequency of and risk factors of SPMs, rather than focusing on the subsequent survival. As far as we know, no study has specifically examined the overall survival (OS) after a diagnosis of LC in patients with a history of EC. The object of the research using data from the Surveillance, Epidemiology, and End
Results (SEER) Program was to examine the incidence and clinical and pathologic characteristics of patients with SPLC after EC and evaluate the effect of a history of EC on OS in patients with SPLC after EC (EC-LC) in comparison with those with LC-1.

Methods

Risk for EC-LC

Patients were identified from SEER 18 registries covering 2000 to 2016. A total of 424 lung cancers occurring greater than or equal to 2 months after EC were identified. The variables examined were sex, race, latency, age at EC diagnosis and year of EC diagnosis. Of these variables, race was evaluated in three categories (white, black, and others). Latency was categorized into four groups (2-11 months, 12-59 months, 60-119 months and ≥120 months). Age was assessed in four categories (<50, 50-59, 60-69, ≥70). Year was categorized into three groups (2000-2004, 2005-2009 and 2010-2016). The expected numbers of second malignancy were calculated for a reference population of identical race and/or ethnicity, attained age, sex, as well as time period. The risk of SPLC was defined as the SIR, which measured the relative strength of association between two malignancies. The SIR was calculated as the ratio of observed to expected second malignancy. Two-sided 95% confidence intervals (CIs) as well as P-values for SIR were based on Poisson exact methods[11], and SIR values were considered significantly elevated at P < 0.05. The criteria of nonoverlapping 95% CIs were utilized to show a statistically significant difference when compared SIRs in different subgroups. The above analysis was performed by using SEER*Stat release 8.3.6.

Characteristics and prognosis of EC-LC and LC-1

A total of 410 EC survivors with ≥1 subsequent lung malignancies were identified. Some of survivors (396 EC patients) developed one primary lung malignancy, and others (14 EC patients) developed two primary lung malignancies. For these patients which developed two primary lung malignancies, their first subsequent lung malignancies were enrolled in the study and the remaining subsequent lung malignancies were eliminated. Finally, we enrolled 410 subsequent lung malignancies in our study. For comparison, three pathological types of LC-1 incuding 108582 first primary lung squamous carcinomas (LUSC-1), 204723 first primary lung adenocarcinomas (LUAD-1), and 66759 first primary small cell lung carcinomas (SCLC-1) were identified in the same SEER registries. Patient and tumor characteristics were compared using chi-square tests with theoretical frequency great than or equal to five. The data were analyzed by continuity correction when theoretical frequency less than five but at least one (less than or equal to 20% cell). Fisher's exact test was utilized as for the rest of it. Standardized adjusted residuals (SARs) for the cell percentage of each subcategory were calculated to determine which cell differences resulted in the statistically significant results. Subcategories had significant difference to the overall percentages when SAR > 1.96 for the percentages of corresponding subcategories. The overall survival (OS) time was calculated from the date of LC diagnosis to the date of last follow-up or death from any
cause. We used the Kaplan-Meier (KM) method and log rank test to compare the OS of EC-LC and LC-1 patients, according to SEER stage (localized, regional, and distant stage) to group. Multivariable analysis was performed by using a Cox regression model to assess the effect on prognosis of a history of EC after adjusting for sex, age at LC diagnosis, race, year of LC diagnosis, LC grade and surgery for LC, according to SEER stage to group. In order to reduce the error generating by misdiagnosis of synchronous primary cancers as SPLC and misclassification of metastatic disease as SPLC, sensitivity analyses were performed by omitting cases with <one-year and <two-year latency to SPLC diagnosis. We analyzed information for all complete cases and applied multiple imputation[12] (5 repetitions) for all cases. The multivariable analysis was performed after using multiple imputation. In addition, propensity score-matching (PSM), subsequently KM analysis and multivariate analysis by Cox regression were conducted to re-assess the effect on prognosis of a history of EC. One-to-four nearest neighbor PSM without replacement was conducted with a caliper width of 0.05 prior to survival analysis. All tests were two-sided. A P < 0.05 was defined as statistically significant. Chi-square tests, continuity correction, Fisher’s exact test, and SAR calculation were performed by SPSS release 25.0. Multiple imputation, KM analysis, Cox regression analysis and PSM were performed by R release 3.6.1.

**Results**

**SIRs for EC**

A total of 44172 patients were diagnosed with EC in the SEER 18 Program database between 2000 and 2016. The characteristics of these patients with EC are shown in Figure 1. Of these cases with EC who were followed for a total of 85011.69 person-years at risk, 424 developed a SPLC. SIR was utilized to evaluate the incidence of SPLC. In comparison with the general population, higher rates of SPLC occurred among patients with EC (SIR = 1.86, 95% CI:1.69-2.05). The risk of developing SPLC was statistically significantly elevated in all subgroups when grouped cases with SPLC according to different standards.

Compared with male EC patients, female had the higher risk for a SPLC, with statistical significance. The risk of developing a SPLC was significantly lower in white patients (SIR 1.74, 95% CI: 1.56-1.93) than black patients (SIR 3.02, 95% CI: 2.31-3.87). For an analysis by latency, the risk (SIR) for a SPLC increased progressively with advancing latency, but with no significant difference. The maximum risk (SIR) was seen for EC patients younger than 50 years (SIR 4.97, 95% CI: 2.78-8.2), which was significantly higher than the risk for patients aged 60-69 years (SIR 2.11, 95% CI: 1.81-2.44) and older than 70 years (SIR 1.29, 95% CI: 1.08-1.51). We noted that there was no significantly increase on the risk (SIR) developing a SPLC during study periods by patient’s year of EC diagnosis.

**Patient and Tumor Characteristics**

Table 1 outlines the patient and EC characteristics for patients with SPLC at time of diagnosis of EC. Among the SPLC histological subtype groups, the distribution of sex, race, latency, age at EC diagnosis,
year of EC diagnosis, stage of EC, site of EC and surgery for EC was similar. The SPLC histological subtypes were associated with histological subtype (P = 0.004) and grade (P = 0.005) of EC (Table 1 and Supplementary Table 1). Patients with secondary primary lung squamous carcinoma after EC (EC-LUSC) were more likely to have a history of esophageal squamous carcinoma (ESC) as 54.0% of them had a history of ESC (SAR = 3.1). Similarly, patients with secondary primary lung adenocarcinoma after EC (EC-LUAD) were more likely to have a history of esophageal adenocarcinoma (EAD) as 58.7% of them had a history of EAD (SAR = 2.6). Individuals with EC-LUAD tended to have a lower grade of EC (53.8%, SAR = 2.8), while individuals with EC-LUSC tended to have a higher grade of EC (68.6%, SAR = 2.9).

Table 2 outlines the baseline characteristics of EC-LUSC and LUSC-1 patients. There was a nonsignificant difference with regard to race, age at lung squamous carcinoma (LUSC) diagnosis and surgery for LUSC between the EC-LUSC and LUSC-1 patients. There was a significantly different distribution of year of LUSC diagnosis (P < 0.001) (Table 2 and Supplementary Table 2). SARs demonstrated that EC-LUSC were more prevalent than LUSC-1 in individuals diagnosed from 2010 to 2016. In addition, sex differed significantly depending on the type of LUSC (P = 0.010), with patients with EC-LUSC more likely to be male. We found a statistically significant difference with respect to grade of disease between the EC-LUSC and LUSC-1 patients (P = 0.008). In comparison with LUSC-1 patients, EC-LUSC patients were more likely to be diagnosed at the well differentiated grade (8.6%, SAR = 2.8). Conversely, LUSC-1 patients tended to be diagnosed at the poorly differentiated and undifferentiated grade (54.4%, SAR = 2.2). There was a significant relationship with regard to stage between the EC-LUSC and LUSC-1 patients (P < 0.001). Patients with EC-LUSC tended to be diagnosed at an earlier stage compared with patients with LUSC.

Table 2 outlines the baseline characteristics of EC-LUAD and LUAD-1 patients. There were no significant differences with regard to surgery for lung adenocarcinoma (LUAD) between the EC-LUAD and LUAD-1 patients, which were similar to the results in the LUSC cohorts (including EC-LUSC and LUSC-1 patients). We found a statistically significant difference with respect to sex, race, age at LUAD diagnosis, year of LUAD diagnosis, stage of LUAD, grade of LUAD, and surgery for LUAD between the EC-LUAD and LUAD-1 patients (Table 2 and Supplementary Table 3). Patients from other races in the EC-LUAD group were more prevalent than those in the LUAD-1 group. Patients with LUAD-1 were more likely to be diagnosed at a younger age than patients with EC-LUAD. Compared with LUAD-1, EC-LUAD were more prevalent in individuals diagnosed in recent years (2010 to 2016). There was a significantly different distribution of sex, with individuals with EC-LUAD tending to be male (P < 0.001). However, the male-female ratio approximately turned out equal for individuals with LUAD-1. In addition, we found that EC-LUAD was significantly more likely to be of lower grade compared with LUAD-1 (P = 0.028). SARs demonstrated that EC-LUAD patients with grade I (well differentiated grade) were more prevalent than LUAD-1 patients with grade I, while EC-LUAD patients with grade III/IV (poorly differentiated and undifferentiated grade) were less prevalent than LUAD-1 patients with grade III/IV. Moreover, The stage of LUAD differed significantly between the EC-LUAD and LUAD patients (P < 0.001). SARs showed that the prevalence of EC-LUAD patients with localized stage was higher, while that with distant stage was lower. Supplementary Table 4 outlines the baseline characteristics of secondary primary small cell lung cancer after EC (EC-SCLC) and the first primary small cell lung cancer (SCLC-1) patients. We did not find a statistically significant
difference with regard to race, age, sex, grade and stage between the SCLC-1 and EC-SCLC patients. However, there was a significant difference with respect to year of diagnosis ($P = 0.007$) (Supplementary Table 4 and Supplementary Table 5). Compared with SCLC-1 patients, EC-SCLC patients were more prevalent in individuals diagnosed earlier this decade (2000 to 2004).

**Survival**

Supplementary Table 6 shows the comparisons of crude survival statistics between EC-LC and LC-1 patients. The leading cause of death among SPLC patients regardless of pathologic types was LC. In comparison with individuals with EC-LUSC, those with LUSC-1 experienced relatively fewer deaths from other cancers, with similar results in patients with other LC pathologic types.

KM methods were used to compute the survival analyses for LUSC and LUAD among survivors of EC and individuals with LC-1 (we did not conduct the survival analyze for SCLC because of sample limitations). A comparison of the unadjusted OS between LUSC-1 and EC-LUSC patients is shown in Table 3. For individuals with LUSC of localized, regional, and distant stage, the median OS of individuals with LUSC-1 was 40 months, 18 months and 7 months, while the median OS of individuals with EC-LUSC was 20 months, 14 months and 7 months, respectively. In comparison with LUSC-1 patients in localized stage, the survival rate of EC-LUSC patients in localized stage was significantly lower ($P < 0.001$). However, these differences in other stages were not found to be statistically significant (regional, $P = 0.140$; distant, $P = 0.229$). Six-month, one-year, two-year and three-year survival rates for EC-LUSC patients in localized stage were 81.0%, 55.3%, 46.7% and 29.5%, respectively. And six-month, one-year, two-year, three-year, five-year and ten-year survival rates for LUSC-1 patients in localized stage were 89.7%, 79.5%, 63.9%, 53.3%, 40.0% and 19.7%, respectively. A comparison of the unadjusted OS between LUAD-1 and EC-LUAD patients is shown in Table 3. For individuals with LUAD of localized, regional, and distant stage, the median OS of individuals with LUAD-1 was 81 months, 33 months and 8 months, while the median OS of individuals with EC-LUAD was 30 months, 34 months and 7 months, respectively. In comparison with the survival rate of LUAD-1 patients in localized stage, the one of EC-LUAD patients in localized stage was significantly lower ($P < 0.001$).

Then multivariable analysis was performed applying a Cox regression modeling to assess the effect of a history of EC in patients with localized stage. We applied this model adjusted for sex, race, age at LC diagnosis, year of LC diagnosis, grade of LC, and surgery for LC. For LUSC in localized stage, results are presented in Table 4 for the 19531 individuals with complete information on all variables as well as subsequently using multiple imputation method for all 24760 individuals. For LUAD in localized stage, results are presented in Table 4 for the 36100 individuals with complete information on all variables as well as subsequently using multiple imputation method for all 44615 individuals. A history of EC was found to be a poor-prognostic factor for LUSC and LUAD patients in localized stage. For LUSC in localized stage, the hazard ratio (HR) for a history of EC was 2.49 (95% CI, 1.75-3.54) in the analysis of the 19531 individuals with complete information and was 1.91 (95% CI, 1.48-3.05) in the analysis of the
24,760 individuals by using multiple imputation method. For LUAD in localized stage, the HR for a history of EC was 2.63 (95% CI, 1.71-4.03) in the analysis of the 36,100 individuals with complete information and was 2.13 (95% CI, 1.48-3.05) in the analysis of the 44,615 individuals by using multiple imputation method. For purpose of reducing the error generating by misdiagnosis of synchronous primary cancers as SPLC and misclassification of metastatic disease as SPLC, we omitted cases with <one-year and <two-year latency to SPLC diagnosis. Whether in LUSC in localized stage or in LUAD in localized stage, results after omitting patients with <one-year and <two-year latency were not changed obviously.

Propensity score-matching analysis was performed to re-evaluate the effect of a history of EC in patients with localized stage. For LUAC in localized stage, a total of 205 patients (41 EC-LUSC patients and 164 LUSC-1 patients) were included after propensity matching. Subsequent KM analysis (Figure 2) and multivariate analysis redemonstrated that a history of EC was a poor-prognostic factor for LUSC (median OS, 20 versus 56 months; HR, 2.37 (95% CI, 1.56-3.60), P < 0.001). A similar result was found for LUAD in localized stage. A total of 192 patients (39 EC-LUAD patients and 153 LUAD-1 patients) were included after propensity matching. Subsequent analyses (Figure 2) showed again that a history of EC correlated with worse prognosis for localized stage LUAD (median OS, 29 versus 110 months; HR, 3.24 (95% CI, 1.84-5.69), P = 0.012).

Discussion

Increased Risk of a SPLC After EC

In this study, we found a statistically significant increase in SPLC risk in all EC survivors in comparison with the incidence rates of general population, with similar results having been reported in some studies[5-8,10], which focused more on the overall second primary cancer risk rather than SPLC risk. In this large population-based study, the data of EC-LC patients were reviewed in more detail and SIRs were assessed for different patient groups with regard to race, latency, age, year of diagnosis and sex. DeSantis et al reported that LC incidence rates are 15% higher in black men than in white men and the opposite was true for women[13]. And they pressed further, and found that higher rates of LC among black men were limited to NSCLC. The majority of EC-SPLC patients in our study were men (73.6%) and NSCLC patients (93.4%). These results maybe account for this phenomenon that the risk (SIR) for a SPLC was higher in black individuals than white individuals, though reasons for this phenomenon were unknown. In this study we found that the risk of developing a SPLC varied between the sexes, with females having the higher risk for a SPLC. According to a major international study[14], male was especially at mortality risk of esophagus cancer, with two or three times the overall mortality rate of female worldwide. In consideration of the better prognosis in female, female with esophagus cancer might be more likely to survive its initial primary cancer (EC) and continue to experience development of a second primary cancer. It was a similar result to a reported 2018 research that claimed that female with initial primary lung cancer was at lower risk for development of a SPLC[15]. The SPLC risk gradually decreased with age at EC diagnosis, which could be most likely caused by the same reason[16-17]. The fact that the total cancer incidence increased when the age of the patients increased might also interpret.
the age-related changes in SIR. In our study, we found that the SPLC risk increased progressively with advancing latency, though with no significant difference. There was a 134% increased risk of developing a SPLC after a latency of >10 years compared to the general population, suggesting a reasonable long-term follow-up protocol should be designed for individuals with EC.

**Patient and Tumor Characteristics**

We observed that the SPLC histological subtypes were associated with histological subtypes of EC. Adjusted standardized residuals demonstrated that the proportion of the EC-LUSC patients which had a history of ESC was significantly higher than that which had a history of other EC histological subtypes. Similarly, the proportion of the EC-LUAD patients which had a history of EAD was significantly higher than that which had a history of other EC histological subtypes. The high frequency of multiple primary carcinoma in patients with lung and upper aerodigestive tract cancers might be explained by the phenomenon of ‘field cancerization’[9,18-20]. One explanation of the concordant histology between EC and subsequent LC might be exposure of the epithelium of lung and upper aerodigestive tract to some of the same carcinogens. Besides, Several master development regulators were significantly altered in squamous cell carcinomas across multiple organ sites, which were drivers of carcinogenesis[21]. These altered regulators in EC might be associated with development of second primary malignancy which was similar to EC in histological subtypes. We also found that the SPLC histological subtypes might be associated with grades of EC. However, around a quarter of EC individuals (23.7%) were unknown grade, therefore the result might be biased and interpreted with the greatest care. We observed that patients with EC-LUSC and EC-LUAD were more often diagnosed in recent years (2010 to 2016) compared to patients with LC-1. These results might be attributed to the improvement of diagnostic technique over time and shorter follow-up intervals of EC patients. In fact, some researches confirmed that cancer survivors received more frequent screening for various subsequent primary cancers than patients without a history of cancer[22-24]. The fact that cancer survivors might receive better surveillance for new cancers also explained why individuals with previous EC tended to diagnosed at an earlier stage compared with LC-1 individuals in this study, which was consistent with previous study[25]. Though we found that patients with EC-LUAC and EC-LUAD were more likely to be diagnosed at a lower grade, this result might be biased because of a large number of patients with unknown grade. In addition, patients with EC-LUSC and EC-LUAD were more likely to be male than patients with LUSC-1 and EC-LUAD respectively, which was perhaps partially reflective of the different male to female ratio between the EC and LC patients in North America. According to a status report on the global burden of cancer in 2018, there was a 4.7-fold variation in esophagus cancer rates by gender in North America, whereas the variation in lung cancer was only 1.3-fold [8], which verified the validity of the above hypothesis.

**Overall Survival**
To the best of our knowledge, this was the first population-based study to specifically examined overall survival of patients with EC-LC. The attention had been paid to investigating the effect of second primary cancer on survival outcomes of patients with EC. Lee et al found that esophageal cancer patients with synchronous second primary cancers had poor survival than that those without them[26]. Kudou et al found a similar result in esophageal cancer patients with metachronous second primary cancers[27]. Different from the past research angles of view that focused on survival outcomes in EC patients with second primary cancer compared with those with first primary EC, The research focused on patients survival outcomes with SPLC, one of the most common second primary cancer of esophagus cancer, by comparing the patients with LC-1. Base on the results of the Kaplan-Meier analysis, we found that in comparison with LUSC-1 patients in localized stage, the survival rate of EC-LUSC patients in localized stage was significantly lower. And similar results were shown in EC-LUAD patients. Subsequent multivariable Cox analyses demonstrated that a history of EC was an independent risk factor of death for LUSC and LUAD patients in localized stage. The survival outcomes of second primary non-small-cell lung cancer individuals had been reported for other primary sites. The survival outcomes of those patients varied with the difference of first primary sites. Budnik et al indicated that a history of head and neck cancer had a detrimental impact on overall survival in survivors who subsequently develop non-small-cell lung cancer regardless of stage[28]. However, US researchers found that a history of breast cancer did not appear to adversely affect overall survival after non-small-cell lung cancer[29]. This study first showed that patients with localized EC-LUSC and EC-LUAD had the inferior survival compared with patients with de novo localized LUSC and LUAD respectively, which were further confirmed with propensity score-matching analyses. We speculate that the inferior overall survival of patients with localized EC-LUSC and EC-LUAD might have been due to more aggressive treatment and host factors inherent to the development of esophagus cancer. Besides, in this study we found that a certain percentage of patients with localized EC-LUSC and EC-LUAD died of first primary cancer (EC). Different survival outcomes in different disease sites might be due to the different magnitude of excess mortality from the antecedent malignancy.

Missing data represented one of the inevitable features of population-based databases including SEER database[30]. Complete case analysis might introduce considerable bias. Therefore we used the multiple imputation approach to handle missing data to reduce the effect of the bias. Subsequent multivariate analyses after applying multiple imputation still indicated that a history of EC was an independent risk factor for poor prognosis in the patients with localized LUSC and LUAD, which were consistent with complete case analyses. Besides, in order to minimizing the potential effects of misclassification of metastatic disease as SPLC and misdiagnosis of synchronous primary cancers as SPLC, cases with <one-year and <two-year latency to SPLC diagnosis were omitted and subsequent multivariate Cox regression analyses were performed. There were no obvious changes in order of magnitude to the HR for localized LUSC and LUAD before and after omitting cases. Sensitivity analyses included multiple imputation of missing values and restriction to cases showed that the results of worse survival for patients with localized EC-LUSC and EC-LUAD compared to those with a de novo localized LUSC and LUAD respectively were stable.
Limitations of Retrospective Data

Regardless of the fact that this population-based study has the advantage of containing a large number of EC survivors who develop SPLC, there are some limitations with regard to retrospective population-based study. First, we left out of consideration other factors potentially having an effect on SPLC risk and survival after SPLC. Some treatment information such as whether or not be treated with radiation and chemotherapy and details of treatment are largely unknown and some important individual patient data such as alcohol status, smoking status, presence of concurrent disease are not provided in the SEER registry. Furthermore, we cannot do a bit deeper analysis for EC-SCLC due to sample limitations and small sample sizes of EC-SCLC may make some research results lose statistical power. Larger studies are needed to evaluate the impact of EC history on the prognosis of patients with EC-SCLC in the future.

Conclusions

The present study provides a broad overview on SPLC after EC, including clinical and pathologic characteristics as well as prognosis. There is a significantly increased risk of SPLC in EC survivors and a history of EC adversely affects OS in individuals who subsequently develop localized EC-LUSC and EC-LUAD. The clinical significances comprise moderately strengthening lung tissue protection and frequent surveillance of the lung during the management of EC patients. Besides, in consideration of the poorer prognosis of localized stage EC-LUSC and EC-LUAD patients after EC, more aggressive treatment is necessary. Larger studies, especially in EC-SCLC and non-localized EC-LUSC and EC-LUAD patients is needed.

List Of Abbreviations

secondary primary lung cancer after primary esophageal cancer: EC-LC; esophageal cancer: EC; first primary lung cancer: LC-1; standardized incidence ratio(s): SIR(s); confidence interval(s): CI(s); secondary primary lung squamous carcinoma after EC: EC-LUSC; first primary lung squamous carcinoma: LUSC-1; secondary primary lung adenocarcinoma after EC: EC-LUAD; first primary lung adenocarcinoma: LUAD-1; first primary small cell lung carcinomas: SCLC-1; secondary primary small cell lung cancer after EC: EC-SCLC; secondary primary malignancy: SPM; Lung cancer: LC; secondary primary lung cancer: SPLC; overall survival: OS; Surveillance, Epidemiology, and End Results: SEER; secondary primary lung cancer after esophageal cancer: EC-LC; Standardized adjusted residual(s): SAR(s); Kaplan-Meier: KM; propensity score-matching: PSM; esophageal adenocarcinoma: EAD; hazard ratio: HR.

Declarations

Ethics approval and consent to participate:

The Second Affiliated Hospital of Nantong University institutional review board exempted this study from review because it uses deidentified publicly available data.
Consent for publication:

All authors agree to submit the article for publication.

Availability of data and material:

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests:

The authors declare that they have no competing interests.

Funding:

This work was supported by Scientific Research Foundation of Nantong Health Committe (grant MB2019004) and Special Project of Clinical Medicine of Nantong University (grants 2019JY002 and 2019JQ006).

Authors' contributions:

Yadong Gao and Junbo Qian contributed to the conception of the study. Yadong Gao, Jianwei Qiu, Liugen Gu, Yanmei Yang, Haifeng Kang, Yong Zhan, Shenglai Zhang, and Yan Zhang contributed significantly to analysis and manuscript preparation. Yadong Gao performed the data analyses and wrote the manuscript. Junbo Qian and Jianwei Qiu helped perform the analysis with constructive discussions.

Acknowledgements:

We want to thank one of Yadong Gao's best friends Shuai Xia, a software engineer for Baidu, for his assistance in data processing. Yadong Gao want to express his gratitude to Alan Tam and Leslie Cheung, two representative figures of the popular music circles in Hong Kong, whose music have given him powerful emotional support over the past years. Besides, Yadong Gao especially want to express his gratitude to Danfeng Li, the girl who he has had a crush on for 12 years. Anyway, Gao do not regret having loved the girl.

References

1. Mitani S, Kadowaki S, Oze I, et al. Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis. Cancer Med. 2020;9(1):394-400.
2. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3

3. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. *J Natl Cancer Inst*. 2017;109(9):djx030. doi:10.1093/jnci/djx030

4. Nandy N, Dasanu CA. Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review. *Curr Med Res Opin*. 2013;29(9):1055-1065. doi:10.1185/03007995.2013.816276

5. Zhu G, Chen Y, Zhu Z, et al. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries. *Dis Esophagus*. 2012;25(6):505-511. doi:10.1111/j.1442-2050.2011.01273.x

6. Chen SC, Teng CJ, Hu YW, et al. Secondary primary malignancy risk among patients with esophageal cancer in Taiwan: a nationwide population-based study. *PLoS One*. 2015;10(1):e0116384. Published 2015 Jan 30. doi:10.1371/journal.pone.0116384

7. Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. *Cancer Epidemiol Biomarkers Prev*. 2008;17(6):1543-1549. doi:10.1158/1055-9965.EPI-07-2876

8. Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. *J Clin Oncol*. 2003;21(23):4336-4341. doi:10.1200/JCO.2003.12.074

9. Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. *Gastroenterology*. 2015;149(7):1700-1715. doi:10.1053/j.gastro.2015.08.054

10. Mitani S, Kadowaki S, Oze I, et al. Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis. *Cancer Med*. 2020;9(1):394-400. doi:10.1002/cam4.2688

11. A J Fox. Statistical methods in cancer research: Volume 2. The design and analysis of cohort studies. *IARC Sci Publ*, 1987, 82(82):1.

12. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med*. 2011;30(4):377-399. doi:10.1002/sim.4067

13. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. *CA Cancer J Clin*. 2019;69(3):211-233. doi:10.3322/caac.21555

14. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424. doi:10.3322/caac.21492
15. Thakur MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, Beebe-Dimmer JL, Wozniak AJ. Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data. *J Thorac Oncol*. 2018;13(1):46-53. doi:10.1016/j.jtho.2017.09.1964

16. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012. http://seer.cancer.gov/csr/1975_2012/ . Accessed March 20, 2017.

17. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. *J Clin Oncol*. 2007;25(35):5570-5577. doi:10.1200/JCO.2007.12.5435

18. Ushijima T. Epigenetic field for cancerization. *J Biochem Mol Biol*. 2007;40(2):142-150. doi:10.5483/bmbrep.2007.40.2.142

19. Baba Y, Yoshida N, Kinoshita K, et al. Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study. *Ann Surg*. 2018;267(3):478-483. doi:10.1097/SLA.0000000000002118

20. Katada C, Yokoyama T, Yano T, et al. Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck. *Gastroenterology*. 2016;151(5):860-869.e7. doi:10.1053/j.gastro.2016.07.040

21. Guan Y, Wang G, Fails D, Nagarajan P, Ge Y. Unraveling cancer lineage drivers in squamous cell carcinomas. *Pharmacol Ther*. 2020;206:107448. doi:10.1016/j.pharmthera.2019.107448

22. Ye Y, Otahal P, Wills KE, Neil AL, Venn AJ. Temporal trends in the risk of second primary cancers among survivors of adult-onset cancers, 1980 through 2013: An Australian population-based study. *Cancer*. 2018;124(8):1808-1818. doi:10.1002/cncr.31247

23. Corkum M, Hayden JA, Kephart G, Urquhart R, Schlievert C, Porter G. Screening for new primary cancers in cancer survivors compared to non-cancer controls: a systematic review and meta-analysis. *J CancerSurviv*. 2013;7(3):455-463. doi:10.1007/s11764-013-0278-6

24. Wang R, Yin Z, Liu L, et al. Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women. *Front Oncol*. 2018;8:427. Published 2018 Oct 9. doi:10.3389/fonc.2018.00427

25. Veit-Rubin N, Rapiti E, Usel M, et al. Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphoma. *Oncologist*. 2012;17(6):783- doi:10.1634/theoncologist.2011-0451

26. Lee JS, Ahn JY, Choi KD, et al. Synchronous second primary cancers in patients with squamous esophageal cancer: clinical features and survival outcome. *Korean J Intern Med*. 2016;31(2):253-259. doi:10.3904/kjim.2014.182

27. Kudou M, Shiozaki A, Fujiwara H, et al. Clinical analysis of esophageal cancer patients with a history of metachronous primary cancer. *Gan To Kagaku Ryoho*. 2014;41(12):2030-2032.

28. Budnik J, DeNunzio NJ, Singh DP, Milano MT. Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and
Survival Outcomes in 3597 Patients [published correction appears in Clin Lung Cancer. *Clin Lung Cancer*. 2020;21(3):195-203. doi:10.1016/j.cllc.2019.02.017

29. Milano MT, Strawderman RL, Venigalla S, Ng K, Travis LB. Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women. *J Thorac Oncol*. 2014;9(8):1081-1090. doi:10.1097/JTO.0000000000000213

30. Hoskin TL, Boughey JC, Day CN, Habermann EB. Lessons Learned Regarding Missing Clinical Stage in the National Cancer Database. *Ann Surg Oncol*. 2019;26(3):739-745. doi:10.1245/s10434-018-07128-3

Tables
| Characteristic | EC-LC | EC-LUSC | EC-LUAD | EC-SCLC | EC-other | P valuea |
|----------------|-------|---------|---------|---------|----------|----------|
| Total          | 410 (100) | 139 (100) | 138 (100) | 27 (100) | 106 (100) |          |
| Sex            |       |         |         |         |          | 0.762    |
| Male           | 303 (73.9) | 103 (74.1) | 105 (76.1) | 18 (66.7) | 77 (72.6) |          |
| Female         | 107 (26.1) | 36 (25.9) | 33 (23.9) | 9 (33.3) | 29 (27.4) |          |
| Race           |       |         |         |         |          | 0.433c   |
| White          | 335 (81.7) | 110 (79.1) | 114 (82.6) | 25 (92.6) | 86 (86.6) |          |
| Non-White      | 75 (18.3) | 29 (20.9) | 24 (17.4) | 2 (7.4) | 20 (18.9) |          |
| Latency        |       |         |         |         |          | 0.08     |
| 2-11 months    | 101 (24.6) | 24 (17.3) | 46 (33.3) | 6 (22.2) | 25 (23.6) |          |
| 12-59 months   | 190 (46.3) | 72 (51.8) | 52 (37.7) | 13 (48.1) | 53 (50.0) |          |
| ≥60 months     | 119 (29.0) | 43 (30.9) | 40 (29.0) | 8 (29.6) | 28 (26.4) |          |
| Age at EC diagnosis |       |         |         |         |          |          |
| <60            | 97 (23.7) | 33 (23.7) | 36 (26.1) | 4 (14.8) | 24 (22.6) | 0.352    |
| 60-69          | 174 (42.4) | 54 (59.0) | 64 (46.4) | 15 (55.6) | 41 (38.7) |          |
| ≥70            | 139 (33.9) | 52 (47.1) | 38 (27.5) | 8 (29.6) | 41 (38.7) |          |
| Year of EC diagnosis |       |         |         |         |          | 0.768    |
| 2000-2004      | 146 (35.6) | 52 (37.4) | 43 (31.2) | 11 (40.7) | 40 (37.7) |          |
| 2005-2009      | 142 (34.6) | 48 (34.5) | 47 (34.1) | 10 (37.0) | 37 (34.9) |          |
| 2010-          | 122 | 39 (28.1) | 48 (34.8) | 69 (22.2) | 29 (27.4) |          |
|             | 2016 (29.8) |          |          |          |          |
|-------------|-------------|----------|----------|----------|----------|
| **Stage of** |             |          |          |          |          |
| **ECd**     |             |          |          |          |          |
| Localized   | 164 (40.0)  | 58 (41.7)| 54 (39.1)| 12 (44.4)| 40 (37.7)| 0.932    |
| Regional/Distant | 206 (50.2)  | 67 (48.2)| 71 (51.4)| 14 (51.9)| 54 (50.9)|          |
| Unknown     | 40 (9.8)    | 14 (10.1)| 13 (9.4) | 1 (3.7)  | 12 (11.3)|          |
| **Histological subtypes of EC** |          |          |          |          |          | 0.004c    |
| Squamous cell carcinoma | 178 (43.4) | 75 (54.0)| 42 (30.4)| 12 (44.4)| 49 (46.2)|          |
| Adenocarcinoma | 203 (49.5)  | 59 (42.4)| 81 (58.7)| 14 (51.9)| 49 (46.2)|          |
| Others      | 29 (7.1)    | 5 (3.6)  | 15 (10.9)| 1 (3.7)  | 8 (7.5)  |          |
| **Grade of ECd** |          |          |          |          |          | 0.005     |
| Well and moderately differentiated | 179 (43.7) | 72 (51.8)| 49 (35.5)| 16 (59.3)| 42 (39.6)|          |
| Poorly differentiated and undifferentiated | 134 (32.7) | 33 (23.7)| 57 (41.3)| 7 (25.9) | 37 (34.9)|          |
| Unknown     | 97 (23.7)   | 34 (24.5)| 32 (23.4)| 4 (14.8) | 27 (25.5)|          |
| **Site of ECd** |          |          |          |          |          | 0.096c    |
| Upper third of esophagus | 28 (6.8)  | 15 (10.8)| 4 (2.9)  | 3 (11.1) | 6 (5.7)  |          |
| Middle third of esophagus | 80 (19.5) | 27 (19.4)| 30 (31.7)| 6 (22.2) | 17 (16.0)|          |
|                      | Lower third of esophagus | Unknown | Surgeryd | Yes | Unknown | No  | Unknown |
|----------------------|--------------------------|---------|----------|-----|---------|-----|---------|
|                      | 227 (55.4)               | 75 (18.3)| 0.304    | 199 | 3 (0.7) | 208 | 3 (0.7) |
|                      | 66 (47.5)                | 31 (22.3)| 70 (50.4) | 70 (50.4) | 68 (48.9) | 68 (48.9) | 1 (0.7) |
|                      | 84 (60.9)                | 20 (14.5) | 73 (52.9) | 73 (52.9) | 64 (46.4) | 64 (46.4) | 1 (0.7) |
|                      | 15 (55.6)                | 3 (11.1)  | 12 (44.4) | 12 (44.4) | 14 (51.9) | 14 (51.9) | 1 (3.7)  |
|                      | 62 (58.5)                | 21 (19.8) | 44 (41.5) | 44 (41.5) | 62 (58.5) | 62 (58.5) | 0        |

Data were presented as n (%) except where otherwise noted.

Abbreviations: EC, esophagus cancer; EC-LC, secondary primary lung cancer after EC; EC-LUSC, secondary primary lung squamous carcinoma after EC; EC-LUAD, secondary primary lung adenocarcinoma after EC; EC-SCLC, secondary primary small cell lung cancer after EC; EC-other LCs, other secondary primary lung cancers after EC.

aP value from Chi-square test except where otherwise noted.

bIncluding Balck, Asian, Native American and Alaska Native/Pacific Islander.

cP value from Fisher's exact test.

dUnknown variables were omitted from Chi-square test and Fisher's exact test.
|                                | LUSC                   |                      | P value<sup>a</sup> | LUAD                   |                      | P value<sup>a</sup> |
|--------------------------------|------------------------|----------------------|----------------------|------------------------|----------------------|----------------------|
| **Total**                      | 139 (100)              | 108582(100)          |                      | 138 (100)              | 204723 (100)         |                      |
| **Sex**                        |                        |                      | 0.010                | <0.001                 |                      |                      |
| Male                           | 103 (74.1)             | 68991 (63.6)         |                      | 105 (76.1)             | 97813 (47.8)         |                      |
| Female                         | 36 (25.9)              | 39591 (36.5)         |                      | 33 (23.9)              | 106910 (52.2)        |                      |
| **Race**                       |                        |                      | 0.323                | 0.011                  |                      |                      |
| White                          | 110 (79.1)             | 89845 (82.7)         |                      | 114 (82.6)             | 162489 (79.4)        |                      |
| Black                          | 23 (16.5)              | 13408 (12.3)         |                      | 21 (15.2)              | 23340 (11.4)         |                      |
| Others<sup>b</sup>             | 6 (4.3)                | 5191 (4.8)           |                      | 3 (2.2)                | 18475 (9.0)          |                      |
| Unknown<sup>c</sup>            | 0                      | 138 (0.1)            |                      | 0                      | 419 (0.2)            |                      |
| **Age at LC diagnosis**        |                        |                      | 0.209                | <0.001                 |                      |                      |
| <60                            | 17 (12.2)              | 19045 (17.5)         |                      | 18 (13.0)              | 53219 (26.0)         |                      |
| 60-69                          | 44 (31.7)              | 34793 (32.0)         |                      | 62 (44.9)              | 63423 (31.0)         |                      |
| ≥70                            | 78 (56.1)              | 54744 (50.4)         |                      | 58 (42.0)              | 88081 (43.0)         |                      |
| **Year of LC diagnosis**       |                        |                      | < 0.001              | <0.001                 |                      |                      |
| 2000-2004                      | 15 (10.8)              | 31150 (28.7)         |                      | 9 (6.5)                | 51951 (25.4)         |                      |
| 2005-2009                      | 35 (25.2)              | 31153 (28.7)         |                      | 32 (23.2)              | 56646 (27.7)         |                      |
| 2010-2016                      | 89 (64.0)              | 46279 (42.6)         |                      | 97 (70.3)              | 96126 (47.0)         |                      |
| **Stage of LC**                |                        |                      | < 0.001              | <0.001                 |                      |                      |
| Localized                      | 58 (41.7)              | 24702 (22.7)         |                      | 56 (40.6)              | 44559 (21.8)         |                      |
|                  | Regional | Distant | Unknown<sup>c</sup> | Grade of LC | Surgery for LC |
|------------------|----------|---------|----------------------|-------------|---------------|
|                  | 32 (23.0)| 37851 (22.8) | 32 (31.5) | 46705 (22.8) |               |
| Distant          | 42 (30.2)| 42561 (39.2) | 43 (31.2) | 108603 (53.0) |               |
| Unknown<sup>c</sup> | 7 (5.0) | 3468 (3.2) | 7 (5.1) | 4856 (2.4) |               |
| **Grade of LC**  |          |         |                      | 0.008<sup>d</sup> | 0.028          |
| Well differentiated | 8 (5.8) | 2427 (2.2) | 21 (15.2) | 19309 (9.4) |               |
| Moderately differentiated | 45 (32.4) | 30218 (27.8) | 36 (26.1) | 46063 (22.5) |               |
| Poorly differentiated and undifferentiated | 40 (28.8) | 38970 (35.9) | 27 (19.6) | 52808 (25.8) |               |
| Unknown<sup>c</sup> | 46 (33.1) | 36967 (34.0) | 54 (39.1) | 86543 (42.3) |               |
| **Surgery for LC** |          |         |                      | 0.265 | 0.063          |
| Yes              | 45 (32.4) | 32414 (29.9) | 57 (41.3) | 70390 (34.4) |               |
| No               | 85 (61.2) | 75168 (69.2) | 78 (56.5) | 133067 (65.0) |               |
| Unknown<sup>c</sup> | 9 (6.5) | 10000 (0.9) | 3 (2.2) | 1266 (0.6) |               |

Data were presented as n (%) except where otherwise noted.

Abbreviations: EC, esophagus cancer; LC, lung cancer; LUSC, lung squamous carcinoma; EC-LUSC, secondary primary LUSC after EC; LUSC-1, first primary LUSC; LUAD, lung squamous carcinoma; EC-LUAD, secondary primary LUAD after EC; LUAD-1, first primary LUAD

<sup>a</sup>P value from Chi-square test except where otherwise noted.

<sup>b</sup>Including Asian, Native American and Alaska Native/Pacific Islander.

<sup>c</sup>Unknown variables were omitted from Chi-square test and Fisher's exact test.

<sup>d</sup>P value from Fisher's exact test.
Table 3 Kaplan-Meier all-cause survival probabilities: patients with EC-LUSC, EC-LUAD, LUSC-1 and LUAD-1

|          | LUSC       |          |          |          |          |
|----------|------------|----------|----------|----------|----------|
|          | EC-LUSC    | LUSC-1   | EC-LUAD  | LUAD-1   |
| Overall  | 139        | 108582   | 138      | 199867   |
| 6 months (SE) | 72.6% (0.038) | 73.4% (0.001) | 81.0% (0.035) | 75.5% (0.001) |
| 1 year (SE) | 47.8% (0.044) | 54.1% (0.002) | 66.3% (0.043) | 59.2% (0.001) |
| 2 year (SE) | 27.8% (0.042) | 35.1% (0.001) | 47.2% (0.048) | 42.6% (0.001) |
| 3 year (SE) | 19.2% (0.038) | 27.0% (0.001) | 33.0% (0.047) | 33.9% (0.001) |
| 5 year (SE) | 13.8% (0.036) | 19.2% (0.001) | 25.7% (0.047) | 24.7% (0.001) |
| 10 year (SE) | Unknown | 9.3% (0.001) | 12.4% (0.049) | 14.4% (0.001) |
| Median, months | 11        | 13        | 22        | 17        |
| P         | 0.023      | 0.681     |          |          |

|          | Localized  |          |          |          |          |
|----------|------------|----------|----------|----------|----------|
|          | 58         | 24702    | 56       | 44559    |
| 6 months (SE) | 81.0% (0.051) | 89.7% (0.002) | 89.0% (0.042) | 95.4% (0.001) |
| 1 year (SE) | 55.3% (0.067) | 79.5% (0.003) | 79.1% (0.056) | 89.9% (0.001) |
| 2 year (SE) | 46.7% (0.069) | 63.9% (0.003) | 64.0% (0.069) | 79.9% (0.002) |
| 3 year (SE) | 29.5% (0.068) | 53.3% (0.003) | 42.3% (0.075) | 71.7% (0.002) |
| 5 year (SE) | Unknown | 40.0% (0.003) | 31.6% (0.078) | 58.8% (0.003) |
| 10 year (SE) | Unknown | 19.7% (0.003) | 31.6% (0.078) | 37.5% (0.003) |
| Median, months | 20        | 40        | 30       | 81       |
| P         | <0.001     | <0.001    |          |          |

|          | Regional   |          |          |          |          |
|----------|------------|----------|----------|----------|----------|
|          | 32         | 37851    | 32       | 46705    |
| 6 months (SE) | 74.1% (0.079) | 81.4% (0.002) | 93.5% (0.044) | 89.7% (0.001) |
| 1 year (SE) | 57.2% (0.090) | 62.8% (0.003) | 83.1% (0.069) | 76.9% (0.002) |
| 2 year (SE) | 22.8% (0.082) | 41.7% (0.003) | 59.7% (0.096) | 59.4% (0.002) |
| 3 year (SE) | 22.8% (0.082) | 31.6% (0.003) | 49.6% (0.103) | 48.0% (0.002) |
| 5 year (SE) | 17.1% (0.079) | 22.4% (0.002) | 44.1% (0.105) | 34.9% (0.002) |
|               | 10 year (SE) | Median, months | P    |
|---------------|--------------|----------------|------|
| Unknown       | 14           | 18             | 0.140|
| 1 year (SE)   | 18           | 34             | 0.971|

| Distant       | 42           | 42561          | 43   | 108603 |
|---------------|--------------|----------------|------|--------|
| 6 months (SE) | 62.7% (0.076)| 57.1% (0.002)  | 60.8% (0.077)| 61.3% (0.001)|
| 1 year (SE)   | 29.0% (0.073)| 32.1% (0.002)  | 35.9% (0.078)| 39.0% (0.002)|
| 2 year (SE)   | 7.7% (0.048) | 14.1% (0.002)  | 13.7% (0.061)| 20.0% (0.001)|
| 3 year (SE)   | 3.9% (0.036) | 8.5% (0.001)   | 6.8% (0.046)| 12.2% (0.001)|
| 5 year (SE)   | Unknown      | 5.0% (0.001)   | 3.4% (0.033)| 6.0% (0.001) |
| 10 year (SE)  | Unknown      | 2.0% (0.001)   | unknown     | 2.4% (0.001)|
| Median, months| 7            | 7              | 7     | 8      |
| P             | 0.229        |                | 0.185  |

Abbreviations: LUSC, lung squamous carcinoma; EC, esophagus cancer; EC-LUSC, secondary primary LUSC after EC; LUSC-1, first primary LUSC; LUAD, lung squamous carcinoma; EC-LUAD, secondary primary LUAD after EC; LUAD-1, first primary LUAD; SE, standard error.
Table 4 Multivariate Cox Regression Analysis evaluating the HR of a History of EC on OS for localized LUSC and localized LUAD.

|                | Localized LUSC | Localized LUAD |
|----------------|----------------|----------------|
|                | All Complete Cases | Multiple Imputation for All Cases | All Complete Cases | Multiple Imputation for All Cases |
| All (n)        | 19531           | 24760          | 36100          | 44615          |
| HR (95% CI)    | 2.49 (1.75-3.54) | 1.91 (1.41-2.59) | 2.63 (1.71-4.03) | 2.13 (1.48-3.05) |
| P              | <0.001          | <0.001         | <0.001         | <0.001         |
| Omitting <one-year Latency (n) | 19524 | 24750 | 36085 | 44594 |
| HR (95% CI)    | 2.50 (1.69-3.70) | 1.82 (1.29-2.56) | 2.51 (1.43-4.43) | 1.89 (1.20-2.99) |
| P              | <0.001          | <0.001         | 0.001          | 0.006          |
| Omitting <two-year Latency (n) | 19514 | 24735 | 36080 | 44587 |
| HR (95% CI)    | 2.62 (1.71-4.02) | 2.22 (1.51-3.27) | 3.47 (1.92-6.28) | 2.13 (1.30-3.48) |
| P              | <0.001          | <0.001         | <0.001         | 0.003          |

Data were presented as HR (95% CI) and P values derived from Cox proportional hazards model adjusted for sex, race, age at LC diagnosis, year of LC diagnosis, grade of LC, and surgery for LC.

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; EC, esophagus cancer; LC, lung cancer; OS, overall survival; LUSC, lung squamous carcinoma; LUAD, lung squamous carcinoma; 95% CI, 95% confidence interval.

Figures
**Figure 1**

Kaplan-Meier Survival curves stratified by the history of EC for localized LUSC and localized LUAD after propensity score-matching analysis. A, localized LUSC; B, localized LUAD Abbreviations: EC, esophagus cancer; EC-LUSC, secondary primary LUSC after EC; LUSC-1, first primary LUSC; LUAD, lung squamous carcinoma; EC-LUAD , secondary primary LUAD after EC; LUAD-1, first primary LUAD.
### Figure 2

Forest plot summarizing risk for SPLC among patients with EC according to patient and treatment. The risk of developing SPLC was statistically significantly elevated in all subgroups ($P < 0.05$). Abbreviations: SPLC, secondary primary lung cancer; EC, esophagus cancer.

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTables.docx